-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Nanjing Chia Tai Tianqing Pharmaceutical submitted its first drug clinical application this year.
Ramelteon is an oral hypnotic drug developed by Takeda of Japan
.
At present, the original research drugs have not been imported in China, and the global sales in 2018 reached 19.
Figure 1: The latest products declared by Nanjing Chia Tai Tianqing
Source: CDE official website
According to the data, ramelteon is the first melatonin receptor agonist used in clinical treatment of insomnia, and it is also the first and so far the only prescription drug for insomnia without abuse and dependence.
It is mainly used for the treatment of insomnia that is difficult to fall asleep.
It also has definite curative effect on chronic insomnia and short-term insomnia
.
According to the data from Minet.
com, Japan's Takeda submitted a clinical application for the import of ramelteon tablets in 2007 and obtained the clinical approval, but has not yet declared for import and marketing
.
More than 10 domestic pharmaceutical companies have obtained clinical approvals for ramelteon tablets.
Figure 2: Domestic clinical situation of ramelteon
Source: new version database of Minet
Wuhan Changlian Laifu Pharmaceutical/Wuhan Xianlu Pharmaceutical Technology carried out the bioequivalence test of ramelteon tablets in 2019.
Table 1: Products declared by Nanjing Chia Tai Tianqing in 2021
Source: MED2.
The R&D strength of Nanjing Chia Tai Tianqing cannot be ignored either.
